Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of

Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation

(2013) Marcos de Lima et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2013) J. L. Pinana et al.   HAEMATOLOGICA

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

(2013) V Bachanova et al.   LEUKEMIA

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

(2012) Veronika Bachanova et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Prophylactic and Preemptive Therapy with Dasatinib after Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

(2012) Giovanni Caocci et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Has MRD monitoring superseded other prognostic factors in adult ALL?

(2012) M. Bruggemann et al.   BLOOD

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

(2012) W. Leung et al.   BLOOD

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

(2012) N. Gokbuget et al.   BLOOD

Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL

(2012) J Sanchez-Garcia et al.   BONE MARROW TRANSPLANTATION

Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults

(2012) Samer K. Khaled et al.   CURRENT OPINION IN ONCOLOGY

Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia

(2012) S Lee et al.   LEUKEMIA

Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP–EBMT analysis

(2012) A Ruggeri et al.   LEUKEMIA

Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: retrospective survey involving 256 patients in Japan

(2012) T Matsumura et al.   LEUKEMIA

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

(2012) H Pfeifer et al.   LEUKEMIA

Favorable Outcome of Unrelated Cord Blood Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

(2011) Yasushi Onishi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Comparison of Unrelated Cord Blood Transplantation and HLA-Mismatched Unrelated Bone Marrow Transplantation for Adults with Leukemia

(2011) Yoshiko Atsuta et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Review

(2011) Denise M. Oliansky et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

(2011) R. Ram et al.   HAEMATOLOGICA

Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source

(2010) Christelle Ferrá et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Philadelphia chromosome-positive acute lymphoblastic leukemia

(2010) Hun J. Lee et al.   CANCER

Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00

(2010) Renato Bassan et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

(2010) R Handgretinger et al.   LEUKEMIA

Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR–ABL-positive acute lymphoblastic leukemia

(2010) S Mizuta et al.   LEUKEMIA

Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic Leukemia

(2009) Anthony S. Stein et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation

(2009) V. Bachanova et al.   BLOOD

Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units

(2009) M. R. Verneris et al.   BLOOD

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993

(2009) Adele K. Fielding et al.   BLOOD

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2009) Seok Lee et al.   CANCER

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

(2009) J.-M. Ribera et al.   HAEMATOLOGICA

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

(2009) O. G. Ottmann et al.   Hematology-American Society of Hematology Education Program

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia

(2008) A Shimoni et al.   LEUKEMIA